Cascadian Therapeutics, Inc.
CASC
CASC was delisted on the 8th of March, 2018.
86 hedge funds and large institutions have $131M invested in Cascadian Therapeutics, Inc. in 2014 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 26 increasing their positions, 26 reducing their positions, and 6 closing their positions.
207% more call options, than puts
Call options by funds: $2.1M | Put options by funds: $686K
200% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 6
20% more capital invested
Capital invested by funds: $110M → $131M (+$21.7M)
16% more funds holding
Funds holding: 74 → 86 (+12)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 26
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$4.59M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
+$2.52M |
| 3 |
State Street
Boston,
Massachusetts
|
+$1.85M |
| 4 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$1.85M |
| 5 |
D.E. Shaw & Co
New York
|
+$782K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Eagle Investment Management
New York
|
-$1M |
| 2 |
PA
Perceptive Advisors
New York
|
-$736K |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$710K |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$588K |
| 5 |
U
UBS
Zurich,
Switzerland
|
-$520K |
CASC Hedge Fund Activity: Q2 2014 in Review
86 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Cascadian Therapeutics, Inc. (CASC) for Q2 2014, worth a combined $131M — up 20% from $110M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new CASC positions and 6 closed out — a net gain of 12 holders — while 26 added to existing stakes and 26 trimmed.
The largest buyer was BlackRock Fund Advisors, adding an estimated $4.59M. The largest seller was First Eagle Investment Management, cutting an estimated $1M.
- 86 institutional investors held Cascadian Therapeutics, Inc. (CASC) as of Q2 2014, up from 74 in Q1 2014.
- Funds reported $131M of Cascadian Therapeutics, Inc. stock for Q2 2014, up 20% quarter-over-quarter.
- 18 funds opened new Cascadian Therapeutics, Inc. positions in Q2 2014 and 6 closed out, a net change of +12 holders.
- The largest Cascadian Therapeutics, Inc. buyer in Q2 2014 was BlackRock Fund Advisors, an estimated $4.59M added.
- The largest Cascadian Therapeutics, Inc. seller in Q2 2014 was First Eagle Investment Management, an estimated $1M sold.
Based on aggregated 13F filings for Q2 2014.